KA/EN
Register
Medicines reference
Search
Search
Active substance

Vitamin E

Favourites

Fat-soluble vitamin, antioxidant. Registered in Georgia: 1 veterinary product. Forms: solution, tablet.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Vitamin E
Georgian name
ვიტამინი E
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 2 forms
Products
Hepatosil Advanced, Vittri-1
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Hepatosil Advanced 30 tablets, Tablet

complementary feed for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder
4.6/10
Weak evidence support
vetman assessment

Hepatosil Advanced

30 tablets, complementary feed for dogs and cats
Assessed clinical scopeDog · Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder · By mouth
Care settingVeterinarian-directed home adjunct with disease-specific treatment and objective clinical/biochemical monitoring
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026

A transparent-category but weakly outcome-supported complementary feed. It may be used as a monitored adjunct, but exact-product evidence, quantitative label transparency and dose/formulation certainty do not support stronger claims.

Regulatory and scientific credibility4.5/10

Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists.

Clinical efficacy3.0/10

Ingredient mechanisms and limited dog studies are plausible, but consensus and reviews find weak clinical-outcome evidence; no Hepatosil trial exists, and recent SAMe+silymarin data showed minimal effect without disease-specific therapy.

Safety and tolerability5.5/10

The ingredients are commonly used adjuncts and serious toxicity is not prominent in indirect sources, but exact-product adverse-event rates, long-term diseased-dog safety, interaction testing and reproductive data are absent.

Clinical practicality6.0/10

Once-daily oral use is manageable, but fasting/food separation, double-coat versus crushing uncertainty, ambiguous dosing above 10 kg and undefined duration add meaningful burden.

Full-course cost-effectiveness-

Current exact Georgian course price and an evidence-based duration were not verified; cost is excluded.

Important safety and use flags

  • This is a complementary feed, not a medicine. Medicine-authorisation status is not applicable; that category does not prove clinical efficacy, pharmaceutical equivalence or regulator-reviewed safety.
  • Adjunct only: diagnose and treat the hepatobiliary disorder. Do not substitute this product for nutrition, toxin-specific care, copper management, antimicrobial/immunosuppressive therapy or biliary intervention.
  • No exact-product clinical-outcome, pharmacokinetic/bioavailability or target-animal safety study was located. Ingredient mechanisms and different formulations cannot be added together as product proof.
  • The manufacturer lists ingredients but not per-tablet quantities or a cat-specific dose. Current quantities and feline instructions come from a retailer reproduction of pack information.
  • At the printed schedule, declared SAMe exposure is about 4.5 mg/kg, materially below commonly referenced stable-salt adjunctive dosing. Do not claim equivalence or increase the blend dose by transferring a single-ingredient regimen.
  • The product is described as double-coated, while the reproduced instructions allow crushing into food. SAMe bioavailability after coat disruption is not established; use one deliberate administration method and monitor response.
  • The feline half-tablet instruction is not supported by a verified score line or equal-dose subdivision. Use a validated small-animal presentation when dose accuracy matters.
  • Review polypharmacy: silymarin may inhibit CYP450 enzymes and P-glycoprotein, but exact-product interaction magnitude is unknown. Avoid assuming that “supplement” means interaction-free.
  • Monitor appetite, GI signs, weight, clinical status and disease-appropriate liver biochemistry/imaging. Stop and reassess if objective benefit is absent or the underlying disease progresses.
  • Safety in pregnancy, lactation, neonates and long-term severe organ disease is not established. Use only after an individual benefit-risk review.
Assessment sources
  1. Hepatosil VetaPro page2026
  2. Hepatosil leaflet copy2026
  3. Hepatosil category audit2026
  4. ACVIM canine hepatitis consensus2019
  5. Canine liver nutraceutical review2013
  6. Canine prednisolone SAMe trial2005
  7. Canine GBM hepatoprotectant trial2025
  8. Canine IV LOLA report2016
  9. Healthy-cat SAMe study2005
  10. Feline acetaminophen SAMe study2003
  11. Veterinary cytoprotectant review2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder
4.1/10
Weak evidence support
vetman assessment

Hepatosil Advanced

30 tablets, complementary feed for dogs and cats
Assessed clinical scopeCat · Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder · By mouth
Care settingVeterinarian-directed home adjunct with disease-specific treatment and objective clinical/biochemical monitoring
vetman score 4.1/10 Weak evidence support
Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026

A weakly supported complementary feed with especially indirect feline evidence and an unvalidated half-tablet dose unit. It should not replace diagnosis, disease-specific treatment or a validated cat-sized product.

Regulatory and scientific credibility4.5/10

Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists.

Clinical efficacy2.5/10

Feline evidence consists mainly of small experimental SAMe studies using different enteric-coated products; it does not establish benefit for spontaneous feline liver disease or this five-ingredient tablet.

Safety and tolerability5.0/10

A small healthy-cat study supports tolerability of a different SAMe product, but exact-formulation safety in ill cats, interactions, long-term use and reproductive groups are unestablished.

Clinical practicality4.5/10

Once-daily use is simple, but the unscored half-tablet dose is not accuracy-validated, fasting and coating/crushing uncertainty remain, and a separate MINI presentation is better matched to small animals.

Full-course cost-effectiveness-

Current exact Georgian course price and an evidence-based duration were not verified; cost is excluded.

Important safety and use flags

  • This is a complementary feed, not a medicine. Medicine-authorisation status is not applicable; that category does not prove clinical efficacy, pharmaceutical equivalence or regulator-reviewed safety.
  • Adjunct only: diagnose and treat the hepatobiliary disorder. Do not substitute this product for nutrition, toxin-specific care, copper management, antimicrobial/immunosuppressive therapy or biliary intervention.
  • No exact-product clinical-outcome, pharmacokinetic/bioavailability or target-animal safety study was located. Ingredient mechanisms and different formulations cannot be added together as product proof.
  • The manufacturer lists ingredients but not per-tablet quantities or a cat-specific dose. Current quantities and feline instructions come from a retailer reproduction of pack information.
  • At the printed schedule, declared SAMe exposure is about 4.5 mg/kg, materially below commonly referenced stable-salt adjunctive dosing. Do not claim equivalence or increase the blend dose by transferring a single-ingredient regimen.
  • The product is described as double-coated, while the reproduced instructions allow crushing into food. SAMe bioavailability after coat disruption is not established; use one deliberate administration method and monitor response.
  • The feline half-tablet instruction is not supported by a verified score line or equal-dose subdivision. Use a validated small-animal presentation when dose accuracy matters.
  • Review polypharmacy: silymarin may inhibit CYP450 enzymes and P-glycoprotein, but exact-product interaction magnitude is unknown. Avoid assuming that “supplement” means interaction-free.
  • Monitor appetite, GI signs, weight, clinical status and disease-appropriate liver biochemistry/imaging. Stop and reassess if objective benefit is absent or the underlying disease progresses.
  • Safety in pregnancy, lactation, neonates and long-term severe organ disease is not established. Use only after an individual benefit-risk review.
Assessment sources
  1. Hepatosil VetaPro page2026
  2. Hepatosil leaflet copy2026
  3. Hepatosil category audit2026
  4. ACVIM canine hepatitis consensus2019
  5. Canine liver nutraceutical review2013
  6. Canine prednisolone SAMe trial2005
  7. Canine GBM hepatoprotectant trial2025
  8. Canine IV LOLA report2016
  9. Healthy-cat SAMe study2005
  10. Feline acetaminophen SAMe study2003
  11. Veterinary cytoprotectant review2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Silymarin250 mg L-Ornithine-L-Aspartate50 mg S-Adenosylmethionine45 mg Artichoke Dry Extract40 mg Vitamin E20 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
VetaPro / Veterinarstvo · Serbia
Registration
Georgia Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 EU Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 UK Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 US Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Adjunctive nutritional/hepatoprotective support only after diagnosis and disease-specific management. The manufacturer states one tablet up to 10 kg daily; a retailer-reproduced leaflet states dog one tablet/10 kg and cat half tablet/5 kg daily on an empty stomach. Do not extend the ambiguous schedule above 10 kg or assume an unscored half is equal-dose. A separate MINI presentation exists for small animals.

Vittri-1, Solution

oral solution, 20 ml for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Full dog label: oral vitamin A, D3 and E drops for prevention and treatment of deficiency of these vitamins
3.9/10
Poor / unconvincing
vetman assessment

Vittri-1

oral solution, 20 ml for dogs and cats
Assessed clinical scopeDog · Full dog label: oral vitamin A, D3 and E drops for prevention and treatment of deficiency of these vitamins · oral
Care settingShort treatment of a diagnosed deficiency or diet error under veterinary control; not routine supplementation of dogs on complete diets
vetman score 3.9/10 Poor / unconvincing
Evidence confidence: Low Georgia: Yes, veterinary · № 001016 · Verified on 21 Oct 2026

A poor option for routine use: high-strength vitamin D3 drops with fixed per-dog doses that can overdose small dogs. Use only for a confirmed deficiency, with weight-based dosing and calcium checks.

Regulatory and scientific credibility3.5/10

Registered in Georgia (001016, valid to 2030) with a current maker instruction, but it has no EU, UK or US authorisation documented in the reviewed evidence and no product study, and the label ties neither need nor dose to a deficiency test.

Clinical efficacy3.5/10

Vitamins A, D3 and E correct a true deficiency, but such deficiency is rare in dogs fed complete commercial diets, and the label gives no diagnostic criteria for the deficiency it treats.

Safety and tolerability3.5/10

Each ml holds 20,000 IU of vitamin D3, roughly 600-700 IU per drop; treatment doses of up to 12 drops daily for 3-4 weeks are fixed per dog, not per kg, so small dogs can receive many times the vitamin D of a complete diet, with a risk of hypercalcaemia and kidney injury.

Clinical practicality6.0/10

Once-daily drops in food are easy to give, but the wide drop ranges are not linked to body weight and the label sets no calcium monitoring.

Full-course cost-effectiveness-

No verified current Georgian price or patient-adjusted course cost was found; foreign prices were not substituted.

Important safety and use flags

  • Do not use in hypervitaminosis, hypercalcaemia or with hypersensitivity; do not combine with other vitamin D products or vitamin D-supplemented diets.
  • Vomiting, anorexia, increased thirst and urination, drooling or weight loss suggest vitamin D toxicity; stop and check serum calcium and kidney values.
  • Doses are per dog, not per kg; in small dogs stay at the low end and keep courses short.
  • Dogs on complete commercial diets do not need routine vitamin A, D or E supplements.
  • Give with a little food or onto the tongue; stop if an allergic reaction occurs.
Assessment sources
  1. AVZ Vittri-12026
  2. Georgia NFA register 20262026
  3. FDA vitamin D pet food alert 20182018
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Full cat label: oral vitamin A, D3 and E drops for prevention and treatment of deficiency of these vitamins
4.1/10
Weak evidence support
vetman assessment

Vittri-1

oral solution, 20 ml for dogs and cats
Assessed clinical scopeCat · Full cat label: oral vitamin A, D3 and E drops for prevention and treatment of deficiency of these vitamins · oral
Care settingShort treatment of a diagnosed deficiency or diet error under veterinary control; not routine supplementation of cats on complete diets
vetman score 4.1/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 001016 · Verified on 21 Oct 2026

A weak option: high-strength vitamin D3 drops with fixed per-cat doses and no deficiency test. Use only for a confirmed deficiency, at the low end, with calcium checks.

Regulatory and scientific credibility3.5/10

Registered in Georgia (001016, valid to 2030) with a current maker instruction, but it has no EU, UK or US authorisation documented in the reviewed evidence and no product study, and the label ties neither need nor dose to a deficiency test.

Clinical efficacy3.5/10

Vitamins A, D3 and E correct a true deficiency, but such deficiency is rare in cats fed complete commercial diets, and the label gives no diagnostic criteria for the deficiency it treats.

Safety and tolerability4.0/10

Each ml holds 20,000 IU of vitamin D3, roughly 600-700 IU per drop; treatment doses of 3-6 drops daily for 3-4 weeks are fixed per cat and can add several thousand IU a day on top of the diet, with a risk of hypercalcaemia.

Clinical practicality6.0/10

Once-daily drops in food are easy to give, but the drop ranges are not linked to body weight and the label sets no calcium monitoring.

Full-course cost-effectiveness-

No verified current Georgian price or patient-adjusted course cost was found; foreign prices were not substituted.

Important safety and use flags

  • Do not use in hypervitaminosis, hypercalcaemia or with hypersensitivity; do not combine with other vitamin D products or vitamin D-supplemented diets.
  • Vomiting, anorexia, increased thirst and urination or weight loss suggest vitamin D toxicity; stop and check serum calcium and kidney values.
  • Avoid in cats with chronic kidney disease or calcium oxalate urolithiasis unless calcium is monitored.
  • Cats on complete commercial diets do not need routine vitamin A, D or E supplements.
  • Give with a little food or onto the tongue; stop if an allergic reaction occurs.
Assessment sources
  1. AVZ Vittri-12026
  2. Georgia NFA register 20262026
  3. FDA vitamin D pet food alert 20182018
Assessed: 23 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Vitamin A15000 IU/ml Cholecalciferol20000 IU/ml Vitamin E10 mg/ml
Formulation Type
Solution
Administration route
oral
Manufacturer
AVZ S-P Ltd · Russia
Manufacturer (register)
AVZ S-P Ltd, Russia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1595, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 01 Dec 2030
Veterinary (National Food Agency)
In the register: ვიტტრი - 1
№ 001016
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗